NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Twist Bioscience Corporation (TWST) Stock Analysis

Twist Bioscience Corporation (TWST) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

TWST

$149.13

+$6.43 (+4.51%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare TWST with… →

TWST Key Statistics

As of Oct 21, 2026
Trading
Open
$138.25
Previous Close
$142.70
Day's Range
138.25–153.80
52-Week Range
23.30–219.71
Volume
2.63M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
2.19
Valuation
Market Cap
$9.89B
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
22.90
EPS (ttm)Profit attributable to each share over the last twelve months.
−2.23
Financials (FY)
Revenue (FY)
$376.57M+20.32%
Net Income (FY)
−$77.67M
Profit marginThe share of revenue left as profit after all costs and taxes.
−31.66%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
66.30M
1-Year Return
+346.63%
Dividend and dates
Earnings Date
November 16, 2026estimated
Avg Volume
2.20M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, TWST closed at $149.13, +346.63% over 1 year.

Twist Bioscience Corporation (TWST) has a market capitalization of $9.89B.

In fiscal 2025, TWST reported revenue of $376.57M.

TWST Stock Return by Calendar Year

Twist Bioscience Corporation (TWST) return since Oct 2018: what $10,000 became

1 year
$10,000 $44,663
+346.63%
5 years
$10,000 $12,402
+24.02%
Since Oct 2018
$10,000 $106,521
+965.21%

If you had invested $10,000 in Twist Bioscience Corporation (TWST) at the close on October 31, 2018, the earliest close on record here, it would have been worth $106,521 at the close on October 21, 2026: +965.21% in total, +34.55% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+370.15%
2025−31.74%
2024+26.07%
2023+54.81%
2022−69.23%
2021−45.23%
2020+572.81%
2019−9.05%
2018 (partial year)+64.93%

As of October 21, 2026.

TWST Revenue and Earnings by Fiscal Year

FY ends September
Fiscal yearRevenueNet incomeNet margin
2025$376.57M−$77.67M−20.6%
2024$312.97M−$208.73M−66.7%
2023$245.11M−$204.62M−83.5%
2022$203.57M−$217.86M−107.0%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$376.57M$191.00M−$136.26M−$77.67M−20.6%
2024$312.97M$133.35M−$175.90M−$208.73M−66.7%
2023$245.11M$89.73M−$206.90M−$204.62M−83.5%
2022$203.57M$84.24M−$249.02M−$217.86M−107.0%

Annual figures as reported, in the company's reporting currency. As of September 30, 2025.

TWST Valuation vs Biotechnology Median

Median of 608 stocks
MetricTWSTBiotechnology medianvs median
P/S ratio22.9013.3072% above
Profit margin−31.66%−38.31%6.6 pts above

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Twist Bioscience Corporation (TWST) at $9.89B. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 979.

The most recent close on file for TWST is $149.13, dated October 21, 2026. That is +$6.43 (+4.51%) against the previous close. Over the past 52 weeks the price has ranged from $23.30 to $219.71. The latest close sits 540.04% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $376.57M. That is +20.32% against the prior fiscal year, when revenue was $312.97M. The same year closed with a net loss of $77.67M. Profit margin runs at −31.66%. That is 6.6 percentage points above the Biotechnology median of −38.31%. Trailing earnings per share are −2.23.

Across the 4 fiscal years on file, revenue moves from $203.57M in 2022 to $376.57M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The price-to-sales ratio is 22.9. On price-to-sales that is 72.19% above the Biotechnology median of 13.3. The medians here are taken across 608 Biotechnology companies that report the metric.

Over the trailing twelve months the total return is +346.63%. Measured over 5 years, that is +4.40% a year compounded. Beta against the wider market is reported at 2.19. Daily returns over the trailing 8 years annualize to a volatility of 79.09%.

Growth & Income

The record shows no dividend for TWST.

The strongest complete calendar year on file is 2020 at +572.81%; the weakest is 2022 at −69.23%. Of the 7 complete calendar years on file, 3 finished higher. 2026 is still running; the total return is +370.15% year to date.

Peer Comparison

Twist Bioscience Corporation (TWST) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Twist Bioscience Corporation TWST $9.89B —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Twist Bioscience Corporation has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Twist Bioscience Corporation

Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. It offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc and Lilly TuneLab. The company was incorporated in 2013 and is headquartered in South San Francisco, California.

Visit website →